Compare General Mills, Inc. (GIS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs TransMedics Group Inc — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: General Mills, Inc. is far larger — about 6.4× TransMedics Group Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and TransMedics Group Inc for 24 Days on average.
| GIS | TMDX | |
|---|---|---|
Market Cap | $17.43B | $2.74B |
Volume | 16,554,362 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $150.42 |
52-Week Low | $31.67 | $61.99 |
Typical Hold Time | 106 Days | 24 Days |
Enterprise Value | $30.61B | $3.13B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, but faces fundamental challenges with negative net income margin (-4.89%) and ROE (-10.55%) for 2026. The stock shows bearish technical signals with mixed earnings performance - missing Q4 2025 estimates but beating Q2 2026. Recent CEO transition to Dana McNabb and a $3 billion cost-saving initiative aim to stabilize operations amid declining revenue trends from $19.5B (2025) to $18.3B (2026).
The stock presents a high-yield opportunity with a $0.61 dividend, but significant risks include persistent margin pressure and rising debt-to-asset ratio (45% in 2025). Analyst consensus is cautious with 61% hold ratings, though the $36 price target suggests 10% upside. Investors should weigh the dividend stability against fundamental deterioration and leadership transition execution risks.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
